CPC Scientific

Executive Summary

CPC Scientific is a well-established US-based contract development and manufacturing organization (CDMO) with over three decades of experience in custom peptide synthesis, oligonucleotide manufacturing, and peptide-oligonucleotide conjugates. Founded in 1992 and headquartered in San Jose, CA, the company supports pharmaceutical and biotechnology clients throughout the product lifecycle—from research-grade materials to full-scale GMP production. Its specialization in complex peptide and oligonucleotide chemistry positions it well in the growing market for targeted therapeutics, including peptide drugs, antisense oligonucleotides, and conjugates. As a private company, CPC Scientific does not disclose financials, but its long operating history and focus on quality and scalability suggest a stable, customer-centric business model. The CDMO sector benefits from increasing outsourcing by pharma companies, and CPC Scientific's expertise in both peptides and oligonucleotides offers a unique value proposition in a fragmented market.

Upcoming Catalysts (preview)

• Q3 2026Capacity expansion for GMP oligonucleotide manufacturing70% success
• Q4 2026Announcement of a strategic partnership with a mid-sized biotech for peptide-drug conjugate development50% success
• H1 2027Launch of enhanced conjugation services for peptide-oligonucleotide therapeutics60% success